iVexSol

IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs. The platform's low-cost, highly scalable Intelligent Vector Solutions are intended to alleviate the vector supply bottleneck and increase access to life-saving treatments for patients.

Intelligent Vector Solutions from iVexSol are revolutionizing the production of LVVs, which are gene delivery vehicles that are a critical raw material in the manufacture of life-changing cell and gene therapies (CGTs). The technology platform employs banks of vector-producing cells to produce LVV in significantly greater quantities than current approaches while allowing for the rapid scale-out required for global demand, all within a smaller manufacturing footprint. These advancements allow for shorter clinical development timelines, lower costs, and, ultimately, greater global access for patients who are waiting for these transformative medicines.

iVexSol headquartered in United States, North America, operates in the Manufacturing sector. The company focuses on Manufacturing and has secured $624.8M in funding across 16 round(s). With a team of 11-50 employees, iVexSol is actively contributing to advancements in Manufacturing. Their latest funding round, Series A - iVexSol, raised $23.8M. Discover more about their projects, partnerships, and impact on our platform.